-+ 0.00%
-+ 0.00%
-+ 0.00%

Arcutis Biotherapeutics Publshes Long-Term Safety And Efficacy Data Of ZORYVE Foam 0.3% In Individuals With Seborrheic Dermatitis In American Journal Of Clinical Dermatology

Benzinga·11/04/2025 13:04:30
Listen to the news
  • ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeks
    • Once-daily ZORYVE foam 0.3% is approved to treat seborrheic dermatitis in adults and adolescents 9 years of age and older